Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
about
Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencingMericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 StudiesAntiviral therapy for chronic hepatitis C in 2014.Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil.Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir.Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals.Global elimination of hepatitis C virus infection: Progresses and the remaining challenges.
P2860
Q28542443-0E8AC091-E085-4764-8251-3002B595E8D3Q34508468-95B8543D-4EBE-4D96-AFB9-E50869FFE4D1Q38221090-977D13D0-A1AA-4526-A2D7-375503E1835EQ38515906-EE98E3E3-F268-421D-AD86-D1AA3E72AC30Q38966979-DC33BB1A-8B66-4773-BC5B-667B50DA0EDDQ42177328-E000F64D-9A9E-460D-8DF2-85D0B5FB39DAQ43100552-8D7E9AAC-90E0-4011-A0B7-2B017EB0A599Q47274792-41CE6004-91BA-4413-8F5D-BBB93A0CB7F7
P2860
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of danopre ...... otype 1 prior null responders.
@en
Efficacy and safety of danopre ...... otype 1 prior null responders.
@nl
type
label
Efficacy and safety of danopre ...... otype 1 prior null responders.
@en
Efficacy and safety of danopre ...... otype 1 prior null responders.
@nl
prefLabel
Efficacy and safety of danopre ...... otype 1 prior null responders.
@en
Efficacy and safety of danopre ...... otype 1 prior null responders.
@nl
P2093
P2860
P356
P1476
Efficacy and safety of danopre ...... notype 1 prior null responders
@en
P2093
Barbara J Brennan
Dominique G Larrey
Edward J Gane
Ellen S Yetzer
Isabel Nájera
Jonathan Q Tran
Nancy S Shulman
Patrick Smith
Peter N Morcos
Rohit Kulkarni
P2860
P304
P356
10.1128/AAC.01515-13
P407
P577
2013-12-02T00:00:00Z